When all patients were classified as 200–400 cells/mm3, 400–800 cells/mm3 and 800–1500 cells/mm3 according to CD4+ cell count regardless of cancer type, the prevalence rates were 16,6% (1/6), 30,5% (22/72) and 6,25% (1/16), respectively. Here, CD4 is linked to cancer.